Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Ivonescimab as Salvage Treatment in Relapsing Pleural Mesothelioma Patients, Previously Treated by Immunotherapy and Standard Chemotherapy

NCT06840834 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT06840834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06840834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Ivonescimab as Salvage Treatment in Relapsing Pleural Mesothelioma Patients, Previously Treated by Immunotherapy and Standard Chemotherapy
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
March 31, 2028
Enrollment
38 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

pleural mesotheliomas